Literature DB >> 22591684

Src, Akt, NF-κB, BCL-2 and c-IAP1 may be involved in an anti-apoptotic effect in patients with BCR-ABL positive and BCR-ABL negative acute lymphoblastic leukemia.

José E Vázquez-Franco1, Elba Reyes-Maldonado, Jorge Vela-Ojeda, Maria L Domínguez-López, Ruth A Lezama.   

Abstract

BCR-ABL kinase has been observed to be potentially related to leukemic cell development. Adult patients with acute lymphoblastic leukemia (ALL) were evaluated to determine whether presence/absence of BCR-ABL induced differences in activation of Src, PI3K/Akt and NF-κB or in the expression of anti-apoptotic proteins such as BCL-2 and c-IAP1. BCR-ABL positive patients showed a significantly higher activation of Src and Akt compared with BCR-ABL negative patients and healthy donors. BCR-ABL negative patients also showed a significant activation of Src and low levels of Akt activation compared with healthy donors. Both patient groups had increased NF-κB activation and overexpression of BCL-2 and c-IAP1. This is the first study to evaluate concurrently in ALL patients presence/absence of BCR-ABL in relation to activation of Src, Akt and NF-κB and the expression of anti-apoptotic proteins. Results suggest that these proteins may be involved in an anti-apoptotic signaling pathway.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22591684     DOI: 10.1016/j.leukres.2012.03.020

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  4 in total

1.  Adult B-cell acute lymphoblastic leukemia cells display decreased PTEN activity and constitutive hyperactivation of PI3K/Akt pathway despite high PTEN protein levels.

Authors:  A Margarida Gomes; Maria V D Soares; Patrícia Ribeiro; Joana Caldas; Vanda Póvoa; Leila R Martins; Alice Melão; Ana Serra-Caetano; Aida B de Sousa; João F Lacerda; João T Barata
Journal:  Haematologica       Date:  2014-02-21       Impact factor: 9.941

2.  The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies.

Authors:  Hae J Chon; Kyoung J Bae; Yura Lee; Jiyeon Kim
Journal:  Front Pharmacol       Date:  2015-03-31       Impact factor: 5.810

3.  M1‑like tumor‑associated macrophages enhance proliferation and anti‑apoptotic ability of liver cancer cells via activating the NF‑κB signaling pathway.

Authors:  Gaowa Sharen; Haidong Cheng; Xiuhua Hu; Jie Miao; Defang Zhao
Journal:  Mol Med Rep       Date:  2022-09-07       Impact factor: 3.423

4.  A novel orally available Syk/Src/Jak2 inhibitor, SKLB-850, showed potent anti-tumor activities in B cell lymphoma (BCL) models.

Authors:  Nannan Zhang; Guo Zhang; Ning Liu; Wanting Lin; Sen Ji; Mingwu Zheng; Kai Chen; Xiao Liang; Guobo Li; Yu Ma; Jun Zhu; Ting Niu; Lin-Li Li; Jiong Li; Yu-Quan Wei; Sheng-Yong Yang
Journal:  Oncotarget       Date:  2017-12-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.